BR112018076639A2 - quimioterapias de combinação - Google Patents

quimioterapias de combinação

Info

Publication number
BR112018076639A2
BR112018076639A2 BR112018076639-9A BR112018076639A BR112018076639A2 BR 112018076639 A2 BR112018076639 A2 BR 112018076639A2 BR 112018076639 A BR112018076639 A BR 112018076639A BR 112018076639 A2 BR112018076639 A2 BR 112018076639A2
Authority
BR
Brazil
Prior art keywords
treatment
oxygen species
cancer
disorders
ero
Prior art date
Application number
BR112018076639-9A
Other languages
English (en)
Inventor
Mousses Spyro
Original Assignee
Systems Oncology, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systems Oncology, Llc filed Critical Systems Oncology, Llc
Publication of BR112018076639A2 publication Critical patent/BR112018076639A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a combinações de agentes que aumentam a quantidade de espécie reativa de oxigênio com agentes que são ativados, intensificados ou induzidos por espécie de oxigênio para o tratamento de câncer e doença pré-cancerosa. composições farmacêuticas compreendendo um agente terapêutico ou fármaco que gera ou produz espécie reativa de oxigênio (ero) em um microambiente da doença, e pelo menos um fármaco ou agente que é ativado, intensificado, ou induzido por ero para o tratamento de câncer em mamífero, transtornos displásicos, transtornos neoplásicos ou hiperproliferativos e a métodos de utilização destas, para o tratamento de câncer em mamífero, transtornos displásicos, transtornos neoplásicos ou hiperproliferativos.
BR112018076639-9A 2016-06-27 2017-06-23 quimioterapias de combinação BR112018076639A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662355293P 2016-06-27 2016-06-27
US62/355,293 2016-06-27
PCT/US2017/038964 WO2018005279A1 (en) 2016-06-27 2017-06-23 Combination chemotherapies

Publications (1)

Publication Number Publication Date
BR112018076639A2 true BR112018076639A2 (pt) 2019-04-02

Family

ID=60787634

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018076639-9A BR112018076639A2 (pt) 2016-06-27 2017-06-23 quimioterapias de combinação

Country Status (13)

Country Link
US (1) US20200179417A1 (pt)
EP (1) EP3558317A4 (pt)
JP (1) JP2019518795A (pt)
KR (1) KR20190025646A (pt)
CN (1) CN109689060A (pt)
AU (1) AU2017291411A1 (pt)
BR (1) BR112018076639A2 (pt)
CA (1) CA3029228A1 (pt)
EA (1) EA201892834A1 (pt)
IL (1) IL263785A (pt)
MX (1) MX2018016332A (pt)
WO (1) WO2018005279A1 (pt)
ZA (1) ZA201808608B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI782018B (zh) * 2017-05-15 2022-11-01 日商濱松赫德尼古斯股份有限公司 導管套組
US11684610B2 (en) 2018-04-09 2023-06-27 Yungjin Pharm. Co., Ltd. Pharmaceutical composition including 1,2-naphthoquinone derivative compound for prevention or treatment of solid cancers or blood cancers
EP3782620B1 (en) * 2018-04-09 2023-12-20 Huen Co., Ltd. Pharmaceutical composition comprising 1,2-naphthoquinone derivative for use in preventing or treating acute myeloid or lymphoblastic leukemia
WO2020246807A2 (ko) * 2019-06-04 2020-12-10 주식회사 엘마이토테라퓨틱스 나프토퀴논 화합물을 포함하는 암 치료용 약학적 조성물
KR102591933B1 (ko) * 2020-02-14 2023-10-23 사회복지법인 삼성생명공익재단 게니핀 및 엘레스클로몰을 포함하는 암 예방 또는 치료용 약학적 조성물
CA3189061A1 (en) * 2020-07-10 2022-01-13 Nadianbio Ltd. Pharmaceutical composition for preventing or treating cancer comprising naphthoquinone-based compound and immune checkpoint inhibitor as active ingredients
CN111965354A (zh) * 2020-07-27 2020-11-20 温州医科大学 Ho-1蛋白在乳腺癌预后评估试剂盒、诊断试剂盒中的应用
CN112516310B (zh) * 2020-12-11 2022-11-29 武汉理工大学 一种肿瘤酸环境响应的纳米前药的制备方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9805866D0 (en) * 1998-03-20 1998-05-13 Zeneca Ltd Anti-tumour agents
US8637490B2 (en) * 2011-07-01 2014-01-28 Uwm Research Foundation, Inc. Anti-cancer agents
PL2768308T3 (pl) * 2011-10-14 2018-12-31 The Board Of Trustees Of The University Of Illinois Związki i substraty przeciwnowotworowe nqo1
CA2883443C (en) * 2012-08-30 2021-01-12 James Sacchettini Compositions and methods for drug-sensitization or inhibition of a cancer cell
WO2014168991A1 (en) * 2013-04-09 2014-10-16 The Board Of Trustees Of The University Of Illinois Tumor-selective combination therapy

Also Published As

Publication number Publication date
EP3558317A1 (en) 2019-10-30
CA3029228A1 (en) 2018-01-04
ZA201808608B (en) 2019-06-26
US20200179417A1 (en) 2020-06-11
IL263785A (en) 2019-01-31
WO2018005279A1 (en) 2018-01-04
MX2018016332A (es) 2019-11-28
JP2019518795A (ja) 2019-07-04
EP3558317A4 (en) 2020-03-18
AU2017291411A1 (en) 2019-01-03
KR20190025646A (ko) 2019-03-11
EA201892834A1 (ru) 2019-07-31
CN109689060A (zh) 2019-04-26

Similar Documents

Publication Publication Date Title
BR112018076639A2 (pt) quimioterapias de combinação
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
BR112019004764A2 (pt) inibidores bicíclicos fundidos da interação menina-mll
BR112017011536A2 (pt) terapias de combinação
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
BR112017028132A2 (pt) métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
BR112015028244A2 (pt) Imunoconjugado que se liga ao folr1 e seu uso
BR112016007479A2 (pt) regimes de dosagem de imunoconjugado de anti-folr1
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112016012410A2 (pt) conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
BR112012026213A8 (pt) Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112015025424A2 (pt) tratamento de câncer usando terapias de combinação de coenzima q10
EA201591925A1 (ru) Терапевтические композиции и их применение
BR112015003751A2 (pt) conjugados da anticorpo-droga (adc) que se ligam a proteínas 158p1d7

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: SYSTEMS ONCOLOGY, LLC (US)

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]